Chartwell Investment Partners LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 29,308 shares of the biotechnology company’s stock, valued at approximately $3,546,000.
Several other large investors also recently made changes to their positions in UTHR. APG Asset Management N.V. bought a new stake in United Therapeutics during the first quarter worth approximately $80,654,000. Norges Bank bought a new position in United Therapeutics in the 4th quarter worth $46,489,000. Robeco Institutional Asset Management B.V. lifted its position in United Therapeutics by 3,487.9% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 524,257 shares of the biotechnology company’s stock worth $63,434,000 after acquiring an additional 509,645 shares during the last quarter. Wedge Capital Management L L P NC acquired a new stake in shares of United Therapeutics in the second quarter valued at about $34,709,000. Finally, Nuveen Asset Management LLC increased its stake in shares of United Therapeutics by 48.9% in the first quarter. Nuveen Asset Management LLC now owns 776,413 shares of the biotechnology company’s stock worth $73,624,000 after purchasing an additional 255,101 shares during the period. 97.99% of the stock is owned by institutional investors.
In other United Therapeutics news, Director Raymond Dwek sold 4,600 shares of United Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $116.81, for a total transaction of $537,326.00. Following the completion of the transaction, the director now directly owns 4,600 shares of the company’s stock, valued at $537,326. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Tommy G. Thompson sold 3,100 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $112.56, for a total transaction of $348,936.00. Following the completion of the sale, the director now owns 9,050 shares in the company, valued at approximately $1,018,668. The disclosure for this sale can be found here. Over the last three months, insiders sold 242,210 shares of company stock valued at $28,840,232. 10.90% of the stock is currently owned by insiders.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 EPS for the quarter, hitting analysts’ consensus estimates of $2.41. The firm had revenue of $362.00 million during the quarter, compared to analysts’ expectations of $339.97 million. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.63 earnings per share. On average, equities analysts forecast that United Therapeutics Co. will post 10.48 earnings per share for the current fiscal year.
UTHR has been the subject of several recent analyst reports. Wedbush restated a “buy” rating and set a $244.00 target price (up previously from $243.00) on shares of United Therapeutics in a research note on Wednesday. BidaskClub downgraded shares of United Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. Cowen reiterated a “buy” rating and set a $145.00 target price on shares of United Therapeutics in a research note on Friday, June 12th. TheStreet lowered shares of United Therapeutics from a “b” rating to a “c” rating in a research report on Wednesday. Finally, Oppenheimer boosted their price objective on shares of United Therapeutics from $155.00 to $165.00 and gave the stock an “outperform” rating in a report on Thursday. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. United Therapeutics presently has a consensus rating of “Hold” and an average target price of $141.67.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.